{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:22:33Z","timestamp":1792606953619,"version":"4.5.0"},"reference-count":106,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Histiocytic sarcoma (HS) is an ultra-rare hematopoietic neoplasm that frequently occurs in extranodal sites of adults. Clinically, HS demonstrates aggressive behavior and can arise de novo or in association with other hematological neoplasms. The median overall survival from the time of diagnosis is approximately six months. Histologically, HS is composed of sheets of large, round to oval cells with abundant eosinophilic cytoplasm and can be confused with a variety of benign and malignant conditions. Immunohistochemistry plays a crucial role in the diagnosis of HS, showing expression of CD163, CD68, lysozyme, and PU.1 and negative staining with follicular dendritic cell markers and myeloid cell markers. Recent studies have demonstrated a high rate of PD-L1 expression, suggesting a potential therapeutic target. Several genomic alterations have been identified in HS, including mutations involving the RAS\/MAPK and PI3K\/AKT\/mTOR signaling pathways, CDKN2A mutations\/deletions, and TP53 mutations. There is no standard protocol for the management of HS. Surgical resection with or without radiotherapy is the most common first-line treatment for unifocal\/localized disease. The systemic treatment options for multifocal\/disseminated disease are very limited. This review provides an overview of the current knowledge on the clinicoradiological features, histopathology, pathogenesis, and management of HS.<\/jats:p>","DOI":"10.3390\/ijms26178554","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:08:46Z","timestamp":1756973326000},"page":"8554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Histiocytic Sarcoma: A Review and Update"],"prefix":"10.3390","volume":"26","author":[{"given":"Yuki","family":"Shinohara","sequence":"first","affiliation":[{"name":"Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-3496","authenticated-orcid":false,"given":"Shizuhide","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-1383","authenticated-orcid":false,"given":"Mikiko","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-8000","authenticated-orcid":false,"given":"Jun","family":"Nishio","sequence":"additional","affiliation":[{"name":"Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref_1","unstructured":"Takahashi, E., and Hung, Y.P. (2024). Histiocytic sarcoma. World Health Organization (WHO) Classification of Haematolymphoid Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: A population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.53.1","article-title":"Histiocytic Sarcoma: An updated literature review based on the 2008 WHO classification","volume":"53","author":"Takahashi","year":"2013","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10428194.2018.1492128","article-title":"Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma","volume":"60","author":"Kommalapati","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: Clinicopathologic analysis of 14 cases of a rare epithelioid malignancy","volume":"28","author":"Hornick","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ejh.12755","article-title":"Histiocytic sarcoma as a secondary malignancy: Pathology, diagnosis, and treatment","volume":"97","author":"Ansari","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0046-8177(88)80209-0","article-title":"Mediastinal germ cell tumors and histiocytosis","volume":"19","author":"Ladanyi","year":"1988","journal-title":"Hum. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/106689690501300314","article-title":"Mediastinal germ cell tumor associated with histiocytic sarcoma of the spleen: Case report of an unusual association","volume":"13","author":"Song","year":"2005","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.clml.2018.07.286","article-title":"Clinicopathologic features and clinical outcome differences in de novo versus secondary histiocytic sarcomas: A multi-institutional experience and review of the literature","volume":"18","author":"Broadwater","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98723","DOI":"10.18632\/oncotarget.21920","article-title":"Prognostic factors for histiocytic and dendritic cell neoplasms","volume":"8","author":"Shimono","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/rg.2021200096","article-title":"Histiocytosis and neoplasms of macrophage-dendritic cell lineages: Multimodality imaging with emphasis on PET\/CT","volume":"41","author":"Huynh","year":"2021","journal-title":"Radiographics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4048\/jbc.2019.22.e32","article-title":"Primary histiocytic sarcoma presenting as a breast mass: A case report","volume":"22","author":"Bang","year":"2019","journal-title":"J. Breast Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.radcr.2023.12.009","article-title":"Histiocytic sarcoma mimicking localized tenosynovial giant cell tumor in the pediatric foot: A rare case report with MRI findings","volume":"19","author":"Khil","year":"2024","journal-title":"Radiol. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1102\/1470-7330.2012.0029","article-title":"Imaging features of primary extranodal histiocytic sarcoma: Report of two cases and a review of the literature","volume":"12","author":"Saboo","year":"2012","journal-title":"Cancer Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/RLU.0b013e3182173979","article-title":"Histiocytic sarcoma involving lymph nodes: Imaging appearance on gallium-67 and F-18 FDG PET\/CT","volume":"36","author":"Makis","year":"2011","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/RLU.0000000000001041","article-title":"Enhanced CT and FDG PET\/CT in histiocytic sarcoma of the pericardium","volume":"41","author":"Dong","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/RLU.0000000000005043","article-title":"FDG PET\/CT imaging of liver and spleen histiocytic sarcoma","volume":"49","author":"Gan","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000002332","article-title":"IRF8 demonstrates positivity in a significant subset of histiocytic and dendritic cell neoplasms","volume":"49","author":"Patwardhan","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/modpathol.2012.175","article-title":"Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions","volume":"26","author":"Sullivan","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.5858\/arpa.2019-0580-OA","article-title":"Hematolymphoid neoplasms rarely mimic undifferentiated pleomorphic sarcoma of soft tissue","volume":"144","author":"Cannatella","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1746-1596-2-7","article-title":"Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component","volume":"2","author":"Alexiev","year":"2007","journal-title":"Diagn. Pathol."},{"key":"ref_22","first-page":"428279","article-title":"Cytogenetics findings in a histiocytic sarcoma case","volume":"2012","author":"Calbacho","year":"2012","journal-title":"Case Rep. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41379-018-0200-x","article-title":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","volume":"32","author":"Shanmugam","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1263","DOI":"10.1002\/onco.13801","article-title":"Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma","volume":"26","author":"Massoth","year":"2021","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","article-title":"Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms","volume":"65","author":"Go","year":"2014","journal-title":"Histopathology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2006.03.028","article-title":"The PTEN and INK4\/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/cncy.21851","article-title":"Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics","volume":"125","author":"Hung","year":"2017","journal-title":"Cancer Cytopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12185-010-0704-8","article-title":"Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18)","volume":"92","author":"Hayase","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/10428191003699845","article-title":"Histiocytic sarcoma arising in indolent small B-cell lymphoma: Report of two cases with molecular\/genetic evidence suggestive of a \u2018transdifferentiation\u2019 during the clonal evolution","volume":"51","author":"Wang","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.humpath.2016.04.004","article-title":"Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma","volume":"55","author":"Bangs","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jnen\/nlae061","article-title":"Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results","volume":"83","author":"Cecchi","year":"2024","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10014-023-00471-8","article-title":"A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: A case report and literature review","volume":"41","author":"Zhang","year":"2024","journal-title":"Brain Tumor Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/PAS.0b013e31819287b8","article-title":"High frequency of clonal immunoglobulin receptor rearrangements in sporadic histiocytic\/dendritic sarcomas","volume":"33","author":"Chen","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/blood-2007-11-124792","article-title":"Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular lymphoma clone","volume":"111","author":"Feldman","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PAS.0b013e3182098799","article-title":"Sequential development of histiocytic sarcoma and diffuse large B-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: A divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual","volume":"35","author":"Wang","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: A study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1200\/JCO.2011.38.8553","article-title":"Histiocytic sarcoma arising from clonally related mantle cell lymphoma","volume":"30","author":"Hure","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12308-009-0031-2","article-title":"Transformation of B cell lymphoma to histiocytic sarcoma: Somatic mutations of PAX-5 gene with loss of expression cannot explain transdifferentiation","volume":"2","author":"Bassarova","year":"2009","journal-title":"J. Hematop."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1600-0560.2011.01769.x","article-title":"Histiocytic sarcoma transdifferentiated from follicular lymphoma presenting as a cutaneous tumor","volume":"38","author":"Zeng","year":"2011","journal-title":"J. Cutan. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Seth, N., Naing, P.T., Singh, R., Geetha, S., Reddy, K., Zhang, X., Yang, T., Caro, J., and Tam, W. (2025). Transdifferentiation of multiple myeloma into histiocytic sarcoma: Case report of a highly unusual phenomenon. Pathobiology.","DOI":"10.1159\/000546669"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"78355","DOI":"10.18632\/oncotarget.13058","article-title":"High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.hoc.2019.08.020","article-title":"Hematologic malignancies","volume":"34","author":"Tseng","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/107327481402100405","article-title":"Dendritic cell and histiocytic neoplasms: Biology, diagnosis, and treatment","volume":"21","author":"Dalia","year":"2014","journal-title":"Cancer Control"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Yanchu, L., Li, Z., Qiongwen, Z., Jiayu, D., and Feng, W. (2024). Case report: Treatment of a rare primary cerebellum histiocytic sarcoma with surgery and radiotherapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1398350"},{"key":"ref_48","first-page":"66","article-title":"Histiocytic sarcoma of the base of tongue treated with radical radiotherapy: A case report and review of the literature","volume":"21","author":"Burton","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12185-007-0008-9","article-title":"Histiocytic sarcoma of the spleen: Case report of asymptomatic onset of thrombocytopenia and complex imaging features","volume":"87","author":"Kobayashi","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ejca.2015.06.109","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_51","first-page":"e25814","article-title":"Histiocytic sarcoma: Clinical features and outcomes of patients treated as a tertiary cancer care center","volume":"14","author":"Sherief","year":"2022","journal-title":"Cureus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2169\/internalmedicine.6948-20","article-title":"Successful treatment of incidental histiocytic sarcoma concomitant with laryngeal carcinoma","volume":"60","author":"Oka","year":"2021","journal-title":"Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.2169\/internalmedicine.8000-16","article-title":"Retroperitoneal bulky histiocytic sarcoma successfully treated with induction chemotherapy followed by curative surgery","volume":"56","author":"Oto","year":"2017","journal-title":"Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2169\/internalmedicine.52.0523","article-title":"Successful treatment of histiocytic sarcoma and concurrent HIV infection using a combination of CHOP and antiretroviral therapy","volume":"52","author":"Narita","year":"2013","journal-title":"Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13000-015-0350-9","article-title":"Histiocytic sarcoma combined with acute monocytic leukemia: A case report","volume":"10","author":"Zhao","year":"2015","journal-title":"Diagn. Pathol."},{"key":"ref_56","first-page":"16808","article-title":"Complete response after chemotherapy and radiotherapy of a tonsillar histiocytic sarcoma with regional lymph node involvement: A case report and review of the literature","volume":"8","author":"Chen","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0377-4929.97891","article-title":"Multifocal histiocytic sarcoma of the gastrointestinal tract","volume":"55","author":"Sundersingh","year":"2012","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wehrmann, S., Rudolph, H., Ernst, D., Siepmann, T., Kaltofen, D., H\u00e4nel, M., and Mirow, L. (2021). Case report: Eighteen month relapse-free survival following radical multidisciplinary oncological treatment in a 68-year-old male patient with histiocytic sarcoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.633215"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12185-014-1630-y","article-title":"Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consideration auto-transplantation","volume":"100","author":"Tsujimura","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1016\/j.radcr.2025.03.045","article-title":"Histiocytic sarcoma involving multiple abdominal sites: A rare case with KRAS mutation and response to ICE chemotherapy","volume":"20","author":"Hussein","year":"2025","journal-title":"Radiol. Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14740\/jh1310","article-title":"Transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma to histiocytic\/dendritic cell sarcoma","volume":"13","author":"Cai","year":"2024","journal-title":"J. Hematol."},{"key":"ref_62","first-page":"728260","article-title":"Successful treatment of multifocal histiocytic sarcoma occurring after renal transplantation with cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) followed by allogeneic hematopoietic stem cell transplantation","volume":"2015","author":"Tomlin","year":"2015","journal-title":"Case Rep. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-017-2202-8","article-title":"Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child","volume":"106","author":"Iwabuchi","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2018.10.004","article-title":"Histiocytic sarcoma associated with follicular lymphoma: Evidence for dramatic response with rituximab and bendamustine alone and a review of the literature","volume":"19","author":"Farris","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00381-015-2815-2","article-title":"Primary cerebral histiocytic sarcoma in childhood: A case report of protracted survival and review of the literature","volume":"31","author":"Foster","year":"2015","journal-title":"Childs Nerv. Syst."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: Analysis of data from the histology-independent, phase 2 open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1212\/WNL.0000000000000880","article-title":"Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib","volume":"83","author":"Idbaih","year":"2014","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00428-017-2176-1","article-title":"Histiocytic and dendritic cell neoplasms: What have we learnt by studying 67 cases","volume":"471","author":"Facchetti","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00277-020-03941-7","article-title":"Trametinib and dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation","volume":"99","author":"Rassidakis","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e28200","DOI":"10.1002\/pbc.28200","article-title":"Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib","volume":"67","author":"Venkataraman","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tan, S.L., Ho, B.L.S., Yew, T.T., and Yunus, D. (2025). an 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib-a case report and literature review. BMC Pediatr., 25.","DOI":"10.1186\/s12887-025-05539-2"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-018-2553-9","article-title":"A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib","volume":"109","author":"Kumamoto","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2022.7001","article-title":"Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation","volume":"20","author":"Hu","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100023","DOI":"10.1016\/j.bneo.2024.100023","article-title":"Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium","volume":"1","author":"Kemps","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","article-title":"Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma","volume":"103","author":"Voruz","year":"2018","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhabitation in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2022.282207","article-title":"Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma","volume":"108","author":"Chohan","year":"2023","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1182\/bloodadvances.2022009349","article-title":"Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms","volume":"7","author":"Durham","year":"2023","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/cncr.26712","article-title":"Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab","volume":"118","author":"Shukla","year":"2012","journal-title":"Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/08880018.2020.1811438","article-title":"Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child: Is it time to consider new targets?","volume":"38","author":"Valera","year":"2021","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ajh.26441","article-title":"Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease","volume":"97","author":"Abeykoon","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e2400471","DOI":"10.1200\/PO-24-00471","article-title":"Personalized medicine in histiocytic disorders: Novel targets in patients without MAPK alterations","volume":"8","author":"Smith","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/sj.leu.2403075","article-title":"Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL","volume":"17","author":"Dalle","year":"2003","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/ajh.20913","article-title":"Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant","volume":"82","author":"Abidi","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1200\/JCO.2010.32.6603","article-title":"Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: A case report and review of the literature","volume":"29","author":"Gergis","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MPH.0b013e3182580d6e","article-title":"Thalidomide therapy for aggressive histiocytic lesions in the pediatric population","volume":"34","author":"Bailey","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_89","first-page":"97","article-title":"Histiocytic sarcoma: Case report of a rare disease in a kidney transplant recipient","volume":"4","author":"Dias","year":"2015","journal-title":"J. Nephropathol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Liu, Z., Xiao, Y., Liu, X., Li, Q., Liu, T., Zhu, F., Wu, G., and Zhang, L. (2021). Case report: Long-term response to radiotherapy combined with targeted therapy in histiocytic sarcoma harboring mutations in MAPK and PI3K\/AKT pathways. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.755893"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3109\/10428194.2011.565840","article-title":"A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant","volume":"52","author":"Mainardi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.3747\/co.19.964","article-title":"long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma","volume":"19","author":"Warsi","year":"2012","journal-title":"Curr. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3109\/10428194.2012.717082","article-title":"Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma","volume":"54","author":"Zeidan","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.36401\/JIPO-23-11","article-title":"Histiocytic sarcoma treated with pembrolizumab: A case report and literature review","volume":"6","author":"Huff","year":"2023","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Nam, H., Min, G.J., Kim, T.Y., Jeon, Y., and Cho, S.G. (2025). Case report: A case series on histiocytic sarcoma-various clinical features and patient outcomes. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1505737"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: Achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e27491","DOI":"10.1002\/pbc.27491","article-title":"Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma","volume":"66","author":"Bose","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.mayocp.2022.05.012","article-title":"Malignant histiocytosis with PD-L1 expression-dramatic response to nivolumab","volume":"97","author":"Campedel","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3892\/mco.2022.2569","article-title":"Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report","volume":"17","author":"Imataki","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.1111\/crj.13741","article-title":"Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis","volume":"18","author":"Lin","year":"2024","journal-title":"Clin. Respir. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1097\/MS9.0000000000001446","article-title":"Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: A case report","volume":"85","author":"Nguyen","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_103","first-page":"23247096241274561","article-title":"Pembrolizumab combined with GDP regimen inducing sustained remission in histiocytic sarcoma: A case report","volume":"12","author":"Gao","year":"2024","journal-title":"J. Investig. High Impact Case Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s13691-022-00562-x","article-title":"A case of refractory cervical primary histiocytic sarcoma treated with pembrolizumab","volume":"30","author":"Furui","year":"2022","journal-title":"Int. Cancer Conf. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1080\/10428194.2025.2478525","article-title":"A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed\/refractory aggressive lymphomas","volume":"66","author":"Merrill","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Zhang, M., Xiao, F., Fang, J., Liu, Z., Shen, Y., Zhu, D., Zhang, Y., Hou, J., and Huang, H. (2024). Long-term remission with novel combined immune-targeted treatment for histiocytic sarcoma accompanied by follicular lymphoma: Case report and literature review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137293"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:38:40Z","timestamp":1760035120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":106,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178554"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178554","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}